Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)‘s stock had its “buy” rating reaffirmed by stock analysts at Cowen and Company in a note issued to investors on Tuesday. They currently have a $40.00 price objective on the stock. Cowen and Company’s price target points to a potential upside of 57.11% from the stock’s current price.

The analysts wrote, “Rhythm released Q3 financials this morning, following the presentation of promising.””

A number of other equities research analysts have also weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Rhythm Pharmaceuticals in a report on Tuesday. Morgan Stanley started coverage on shares of Rhythm Pharmaceuticals in a report on Monday, October 30th. They set an “equal weight” rating and a $23.00 price target for the company. Finally, Bank of America Corporation initiated coverage on shares of Rhythm Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $30.00 price target for the company.

Shares of Rhythm Pharmaceuticals (RYTM) traded up $1.25 on Tuesday, hitting $25.46. 100,300 shares of the stock were exchanged, compared to its average volume of 284,493. Rhythm Pharmaceuticals has a 1 year low of $21.38 and a 1 year high of $33.81.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/14/rhythm-pharmaceuticals-inc-rytm-given-buy-rating-at-cowen-and-company.html.

In related news, Director David P. Meeker acquired 25,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was acquired at an average cost of $17.00 per share, with a total value of $425,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider James E. Flynn acquired 355,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The shares were bought at an average cost of $17.00 per share, with a total value of $6,035,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 1,285,000 shares of company stock worth $21,845,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.